Amanta Healthcare IPO

Well-Established Pharmaceutical Company: Amanta Healthcare has a long track record in the pharma sector with a wide and diverse product base, ranging from IV fluids to medical devices. This strong foundation enhances its credibility and growth potential.

Strong Domestic and International Network: The company has a robust marketing presence in India through 320 distributors and stockists, along with a global footprint across Africa, Latin America, the UK, and other regions. Its international expansion provides stability and diversified revenue streams.

Large-Scale Manufacturing Capabilities: With advanced facilities utilizing ABFS and ISBM technologies, Amanta Healthcare is capable of producing a high volume of sterile liquid products, ensuring consistent supply to meet rising market demand.

Skilled Workforce and Experienced Management: A team of more than 1,700 employees and a promoter group with decades of industry experience strengthen the company’s operational efficiency and long-term vision.

High Debt Levels: The company carries a Debt-to-Equity ratio of 2.02, which indicates a high dependence on borrowings. This could affect profitability if debt servicing costs rise.

Declining Revenue Trend: Although profits improved, revenue in FY25 witnessed a 2% decline compared to FY24, reflecting challenges in top-line growth. Sustained revenue expansion remains critical for long-term performance.

Dilution of Promoter Holding: Promoter shareholding will reduce significantly from 85.60% pre-IPO to 63.56% post-IPO, which may impact promoter control and investor confidence.

High Valuation Concerns: At a Post-issue P/E of 46.59x, the IPO is priced on the higher side compared to some industry peers. This raises concerns regarding its valuation attractiveness for investors.